Table 1 SITC 2018 Biomarkers Workshop Data Sharing Partnerships
From: SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art
Name of Institution | Objective (related to IO/Biomarkers) | Perspective |
|---|---|---|
National Cancer Institute (NCI) | Address knowledge gaps in cancer immunotherapy to optimize clinical trial design. Developed the CIMAC-CIDC Network from the Cancer Moonshot Initiative to establish a standing network of laboratories and data commons for a systematic approach to biomarker discovery and validation. | Government |
Cancer Immune Monitoring and Analysis Centers (CIMAC) and Cancer Immunologic Data Commons (CIDC) Network | Provide systematic support for correlative studies in immunotherapy trials through a standing network of laboratory centers (CIMACs) for immune profiling and analysis, and a data center (CIDC) for data repository, integration and analytical pipelines. The goal is to build the framework for a sustainable immuno-oncology data resource serving the NCI trial networks and funded programs and eventually the larger research community. | Government-Academic-Private Partnership |
Foundation for the National Institutes of Health (FNIH) | Accelerate biomedical research through collaborations between NIH and leading public and private institutions. (E.g. FNIH manages the Biomarkers Consortium, a public-private biomedical research partnership for identification and development of high-impact biomarkers.) | Government |
The Partnership for Accelerating Cancer Therapies (PACT) | Enhance ongoing efforts within the CIMAC-CIDC network to provide a systematic approach to IO biomarker investigation in clinical trials. | Public-Private Partnership |
Parker Institute for Cancer Immunotherapy (PICI) | Utilize a collaboration-based model with specific considerations for standardized data and specimen sharing across all platforms. | Public-Private Partnership |
Cancer Immunotherapy Trials Network (CITN) | Pair cutting edge clinical trials with correlative biomarker studies. Implementation of centralized operations, quality specimen collection and processing, competent biobanking, protocols and amendment management, real-time immune monitoring assays, collaborations with expert laboratories, and standardized data integration. | Academia |
Biden Cancer Initiative | Develop and drive progress in cancer research, especially in assay/data standardization and harmonization - under Vice President Biden and Dr. Jill Biden’s Moonshot Initiative. | Non-profit |
National Institute of Standards and Technology (NIST) | Apply transparent, open-sourced standards to cancer research and clinical care. | Public-Private Partnership |
Alliance-NCI irAE Biorepository | Provide an efficient centralized repository for acquisition, organization and distribution of biospecimens in clinical trials; to improve treatment of severe irAEs. | Public-Private Partnership |
Bill & Melinda Gates Medical Research Institute (The Gates Foundation) | Utilize IO biomarker strategies to develop drugs and vaccines for tuberculosis, malaria and enteric disease. | Non-profit |